| Pair Name | Forskolin, Ponatinib | ||
| Phytochemical Name | Forskolin (PubChem CID: 47936 ) | ||
| Anticancer drug Name | Ponatinib (PubChem CID: 24826799 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Forskolin, Ponatinib | |||
| Disease Info | [ICD-11: 2A20.1] | Chronic myelogenous leukemia | Investigative | |
| Gene Regulation | Down-regulation | Phosphorylation | CRKL | hsa1399 |
| In Vitro Model | KCL-22 | Chronic myelogenous leukemia, BCR-ABL1 positive | Homo sapiens (Human) | CVCL_2091 |
| K-562 | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0004 | |
| HH [Human lymphoma] | Primary cutaneous T-cell non-Hodgkin lymphoma | Homo sapiens (Human) | CVCL_1280 | |
| HEK293 | Healthy | Homo sapiens (Human) | CVCL_0045 | |
| Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 | |
| Result | This study provides new insight into the biological underpinnings of BCR-ABL-driven CML and potential rationale for investigating novel treatment strategies for patients with T315I CML. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumour Biol. 2016 Sep;37(9):12643-12654. doi: 10.1007/s13277-016-5179-7. | Click |
